Skip to main content
Top
Published in: BMC Nephrology 1/2022

Open Access 01-12-2022 | Vasculitis | Case report

Acquired aplastic anemia complicated with anti-glomerular basement membrane disease successfully treated with immunosuppressive therapy: a case report

Authors: Kenji Matsui, Wataru Kamata, Yasuhiro Mochida, Kunihiro Ishioka, Hidekazu Moriya, Sumi Hidaka, Takayasu Ohtake, Yotaro Tamai, Shuzo Kobayashi

Published in: BMC Nephrology | Issue 1/2022

Login to get access

Abstract

Background

Aplastic anemia (AA) is a rare but fatal disorder characterized by pancytopenia due to bone marrow hypoplasia. Anti-glomerular basement membrane disease (anti-GBM disease) is an immune complex small-vessel vasculitis that presents as rapidly progressive glomerulonephritis and/or pulmonary hemorrhage. Although both involve autoreactive T cells that are partially triggered by human leukocyte antigen (HLA)-DR15, there have been no reports of their co-existence and the treatment strategy is not well understood.

Case presentation

A 67-year-old woman presented with fever, malaise, and acute kidney injury with proteinuria and hematuria requiring hemodialysis. She was diagnosed with anti-GBM antibody disease based on high serum anti-GBM antibody titer and crescentic glomerulonephritis on a renal biopsy. Pulse administration of methylprednisolone (MP), oral prednisolone (PSL), and plasmapheresis were performed. Only 2 weeks after the diagnosis of anti-GBM disease, the patient developed pancytopenia requiring frequent blood transfusions. The blood cell count did not recover even 1 month after discontinuing the drugs that could cause pancytopenia. Bone marrow examination showed hypocellularity without abnormal infiltrates or fibrosis, which led to the diagnosis of severe acquired AA. Further HLA phenotyping revealed that she had HLA-DR15. Increased dose of PSL with the secondary MP pulse and the addition of cyclosporine improved pancytopenia. Although she remained dialysis-dependent, anti-GBM disease and pancytopenia did not recur for more than 2 years.

Conclusions

We report the first case of acquired AA complicated with anti-GBM disease in an elderly woman with HLA-DR15, which was successfully treated with immunosuppressive therapy (IST). This report is valuable not only because it shows they may co-occur, but also because it provides a therapeutic option for this complex condition. It was also suggested that pancytopenia in patients with anti-GBM disease recalls serious hematologic diseases including AA that require immediate treatment based on bone marrow examination.
Literature
1.
go back to reference Vaht K, Göransson M, Carlson K, et al. Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000–2011. Haematologica. 2017;102(10):1683–90.CrossRef Vaht K, Göransson M, Carlson K, et al. Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000–2011. Haematologica. 2017;102(10):1683–90.CrossRef
2.
go back to reference Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international Chapel Hill consensus conference nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11.CrossRef Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international Chapel Hill consensus conference nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11.CrossRef
3.
go back to reference Miano M, Dufour C. The diagnosis and treatment of aplastic anemia: a review. Int J Hematol. 2015;101(6):527–35.CrossRef Miano M, Dufour C. The diagnosis and treatment of aplastic anemia: a review. Int J Hematol. 2015;101(6):527–35.CrossRef
4.
go back to reference Stalder MP, Rovo A, Halter J, et al. Aplastic anemia and concomitant autoimmune diseases. Ann Hematol. 2009;88(7):659–65.CrossRef Stalder MP, Rovo A, Halter J, et al. Aplastic anemia and concomitant autoimmune diseases. Ann Hematol. 2009;88(7):659–65.CrossRef
5.
go back to reference Singh NP, Prakash A, Garg D, et al. Aplastic anemia complicating systemic lupus erythematosus: successful management with cyclosporine. Rheumatol Int. 2004;24(1):40–2.CrossRef Singh NP, Prakash A, Garg D, et al. Aplastic anemia complicating systemic lupus erythematosus: successful management with cyclosporine. Rheumatol Int. 2004;24(1):40–2.CrossRef
6.
go back to reference Matsumoto N, Kagawa H, Ichiyoshi H, et al. Aplastic anemia complicating Sjogren's syndrome. Intern Med. 1997;36(5):371–4.CrossRef Matsumoto N, Kagawa H, Ichiyoshi H, et al. Aplastic anemia complicating Sjogren's syndrome. Intern Med. 1997;36(5):371–4.CrossRef
7.
go back to reference Pamuk GE, Pamuk ON, Umit EG, Puyan FO, Ozturk E, Demir M. Antineutrophil cytoplasmic antibody associated vasculitis in one patient with severe aplastic anemia: description of the first case. Leuk Res. 2009;33(8):e95–7.CrossRef Pamuk GE, Pamuk ON, Umit EG, Puyan FO, Ozturk E, Demir M. Antineutrophil cytoplasmic antibody associated vasculitis in one patient with severe aplastic anemia: description of the first case. Leuk Res. 2009;33(8):e95–7.CrossRef
8.
go back to reference McAdoo SP, Pusey CD. Anti-glomerular basement membrane disease. Clin J Am Soc Nephrol. 2017;12(7):1162–72.CrossRef McAdoo SP, Pusey CD. Anti-glomerular basement membrane disease. Clin J Am Soc Nephrol. 2017;12(7):1162–72.CrossRef
9.
go back to reference Zhang M, Guan N, Zhu P, et al. Recurrent anti-GBM disease with T-cell large granular lymphocytic leukemia: a case report. Medicine. 2019;98(31):e16649.CrossRef Zhang M, Guan N, Zhu P, et al. Recurrent anti-GBM disease with T-cell large granular lymphocytic leukemia: a case report. Medicine. 2019;98(31):e16649.CrossRef
10.
go back to reference Gu Q-H, Jia X-Y, Hu S-Y, et al. The clinical and immunologic features of patients with combined anti-GBM disease and castleman disease. Am J Kidney Dis. 2018;71(6):904–8.CrossRef Gu Q-H, Jia X-Y, Hu S-Y, et al. The clinical and immunologic features of patients with combined anti-GBM disease and castleman disease. Am J Kidney Dis. 2018;71(6):904–8.CrossRef
11.
go back to reference Basnet A, Cholankeril MR. Hemophagocytic lymphohistiocytosis in a patient with Goodpasture's syndrome: a rare clinical association. Am J Case Rep. 2014;15:431–6.CrossRef Basnet A, Cholankeril MR. Hemophagocytic lymphohistiocytosis in a patient with Goodpasture's syndrome: a rare clinical association. Am J Case Rep. 2014;15:431–6.CrossRef
12.
go back to reference Wang J, Jelcic I, Mühlenbruch L, et al. HLA-DR15 molecules jointly shape an autoreactive T cell repertoire in multiple sclerosis. Cell. 2020;183(5):1264–1281.e20.CrossRef Wang J, Jelcic I, Mühlenbruch L, et al. HLA-DR15 molecules jointly shape an autoreactive T cell repertoire in multiple sclerosis. Cell. 2020;183(5):1264–1281.e20.CrossRef
13.
go back to reference Sugimori C, Yamazaki H, Feng X, et al. Roles of DRB1∗1501 and DRB1∗1502 in the pathogenesis of aplastic anemia. Exp Hematol. 2007;35(1):13–20.CrossRef Sugimori C, Yamazaki H, Feng X, et al. Roles of DRB1∗1501 and DRB1∗1502 in the pathogenesis of aplastic anemia. Exp Hematol. 2007;35(1):13–20.CrossRef
14.
go back to reference Kitagawa W, Imai H, Komatsuda A, et al. The HLA-DRB1*1501 allele is prevalent among Japanese patients with anti-glomerular basement membrane antibody-mediated disease. Nephrol Dial Transplant. 2008;23(10):3126–9.CrossRef Kitagawa W, Imai H, Komatsuda A, et al. The HLA-DRB1*1501 allele is prevalent among Japanese patients with anti-glomerular basement membrane antibody-mediated disease. Nephrol Dial Transplant. 2008;23(10):3126–9.CrossRef
15.
go back to reference Cattran DC, Feehally J, Cook HT, Liu ZH, Fervenza FC, Mezzano SA, et al. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2012;2(2):139–274.CrossRef Cattran DC, Feehally J, Cook HT, Liu ZH, Fervenza FC, Mezzano SA, et al. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2012;2(2):139–274.CrossRef
16.
go back to reference Seiki Y, Sasaki Y, Hosokawa K, et al. Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome: a reliable marker for a benign subset of bone marrow failure. Haematologica. 2013;98(6):901–7.CrossRef Seiki Y, Sasaki Y, Hosokawa K, et al. Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome: a reliable marker for a benign subset of bone marrow failure. Haematologica. 2013;98(6):901–7.CrossRef
17.
go back to reference Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000;96(6):2049–54.CrossRef Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000;96(6):2049–54.CrossRef
18.
go back to reference Dunckley H, Chapman JR, Burke J, et al. HLA-DR and -DQ genotyping in anti-GBM disease. Dis Markers. 1991;9(5):249–56.PubMed Dunckley H, Chapman JR, Burke J, et al. HLA-DR and -DQ genotyping in anti-GBM disease. Dis Markers. 1991;9(5):249–56.PubMed
19.
go back to reference Huey B, McCormick K, Capper J, et al. Associations of HLA-DR and HLA-DQ types with anti-GBM nephritis by sequence-specific oligonucleotide probe hybridization. Kidney Int. 1993;44(2):307–12.CrossRef Huey B, McCormick K, Capper J, et al. Associations of HLA-DR and HLA-DQ types with anti-GBM nephritis by sequence-specific oligonucleotide probe hybridization. Kidney Int. 1993;44(2):307–12.CrossRef
20.
go back to reference Fisher M, Pusey CD, Vaughan RW, Rees AJ. Susceptibility to anti-glomerular basement membrane disease is strongly associated with HLA-DRB1 genes. Kidney Int. 1997;51(1):222–9.CrossRef Fisher M, Pusey CD, Vaughan RW, Rees AJ. Susceptibility to anti-glomerular basement membrane disease is strongly associated with HLA-DRB1 genes. Kidney Int. 1997;51(1):222–9.CrossRef
21.
go back to reference Kapusttn SI, Popova TI, Lyschov AA, Togo AV, Abdulkadyrov KM, Blinov MN. HLA-DR2 frequency increase in severe aplastic anemia patients is mainly attributed to the prevalence of DR15 subtype. Pathol Oncol Res. 1997;3(2):106–8.CrossRef Kapusttn SI, Popova TI, Lyschov AA, Togo AV, Abdulkadyrov KM, Blinov MN. HLA-DR2 frequency increase in severe aplastic anemia patients is mainly attributed to the prevalence of DR15 subtype. Pathol Oncol Res. 1997;3(2):106–8.CrossRef
22.
go back to reference Saunthararajah Y, Nakamura R, Nam J-M, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood. 2002;100(5):1570–4.CrossRef Saunthararajah Y, Nakamura R, Nam J-M, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood. 2002;100(5):1570–4.CrossRef
23.
go back to reference Qahtani SAA. Drug-induced megaloblastic, aplastic, and hemolytic anemias: current concepts of pathophysiology and treatment. Int J Clin Exp Med. 2018;11(6):5501–12. Qahtani SAA. Drug-induced megaloblastic, aplastic, and hemolytic anemias: current concepts of pathophysiology and treatment. Int J Clin Exp Med. 2018;11(6):5501–12.
24.
go back to reference Yu Z, Hu J, Hu Y. Neutropenia and thrombocytopenia induced by proton pump inhibitors: a case report. Drug Saf Case Rep. 2018;5(1):28.CrossRef Yu Z, Hu J, Hu Y. Neutropenia and thrombocytopenia induced by proton pump inhibitors: a case report. Drug Saf Case Rep. 2018;5(1):28.CrossRef
25.
go back to reference Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108(8):2509–19.CrossRef Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108(8):2509–19.CrossRef
26.
go back to reference Kaufman DW, Kelly JP, Jurgelon JM, et al. Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol Suppl. 1996;60:23–30.PubMed Kaufman DW, Kelly JP, Jurgelon JM, et al. Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol Suppl. 1996;60:23–30.PubMed
27.
go back to reference Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187–207.CrossRef Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187–207.CrossRef
28.
go back to reference Ilhan O, Beksac M, Koc H, et al. HLA-DR frequency in Turkish aplastic anemia patients and the impact of HLA-DR2 positivity in response rate in patients receiving immunosuppressive therapy. Blood. 1995;86(5):2055.CrossRef Ilhan O, Beksac M, Koc H, et al. HLA-DR frequency in Turkish aplastic anemia patients and the impact of HLA-DR2 positivity in response rate in patients receiving immunosuppressive therapy. Blood. 1995;86(5):2055.CrossRef
29.
go back to reference Morishita Y, Matsukawa Y, Kura Y, et al. Antithymocyte globulin for a patient with systemic lupus erythematosus complicated by severe pancytopenia. J Int Med Res. 1997;25(4):219–23.CrossRef Morishita Y, Matsukawa Y, Kura Y, et al. Antithymocyte globulin for a patient with systemic lupus erythematosus complicated by severe pancytopenia. J Int Med Res. 1997;25(4):219–23.CrossRef
Metadata
Title
Acquired aplastic anemia complicated with anti-glomerular basement membrane disease successfully treated with immunosuppressive therapy: a case report
Authors
Kenji Matsui
Wataru Kamata
Yasuhiro Mochida
Kunihiro Ishioka
Hidekazu Moriya
Sumi Hidaka
Takayasu Ohtake
Yotaro Tamai
Shuzo Kobayashi
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2022
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-022-02772-0

Other articles of this Issue 1/2022

BMC Nephrology 1/2022 Go to the issue